Loading the company…
Loading the company…
Families: Skin substitutes & wound grafts.
All companies · Product and company coverage
In the last ten years FDA made 1 decision for Biotissue Holdings (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2026 (1). The latest was on 2026-06-05.
| Family | Decisions on record |
|---|---|
| Skin substitutes & wound grafts | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-06-05 | 510(k) | K253204 | Catalyze |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Biotissue Holdings.
In 2025, Biotissue Holdings reported engagement with 590 surgeons and other clinicians in the states MedaRep covers, worth $517K in consulting, speaking, meals and travel for its device products, the most in North Carolina ($109K to 19). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: North Carolina ($109K, 19 engaged), New Jersey ($77K, 40 engaged), Texas ($53K, 42 engaged), Louisiana ($41K, 44 engaged), Florida ($34K, 61 engaged).